^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CB CAR-NK019
i
Other names: CB CAR-NK019, anti-CD19 CAR-NK
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Zhejiang University
Drug class:
CD19 inhibitor, NK cell stimulant
Related drugs:
9ms
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL (clinicaltrials.gov)
P1, N=48, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Enrolling by invitation --> Recruiting
Enrollment status
|
CD19 (CD19 Molecule)
|
CD20 negative
|
CB CAR-NK019
10ms
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/relapsed Central Nervous System Lymphoma (clinicaltrials.gov)
P1, N=42, Enrolling by invitation, Second Affiliated Hospital, School of Medicine, Zhejiang University
New P1 trial
|
CB CAR-NK019
10ms
Anti-CD19 IL-10 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases (clinicaltrials.gov)
P=N/A, N=15, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting | Trial completion date: Nov 2027 --> Jan 2027
Enrollment open • Trial completion date
|
cyclophosphamide • fludarabine IV • CB CAR-NK019
11ms
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL (clinicaltrials.gov)
P1, N=48, Enrolling by invitation, Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting --> Enrolling by invitation | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Dec 2025
Enrollment status • Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule)
|
CD19 expression • CD20 negative
|
CB CAR-NK019
1year
Anti-CD19 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases (clinicaltrials.gov)
P=N/A, N=15, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
New trial
|
cyclophosphamide • CB CAR-NK019
over1year
Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus (clinicaltrials.gov)
P1, N=10, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
Enrollment open
|
cyclophosphamide • CB CAR-NK019
over1year
Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus (clinicaltrials.gov)
P1, N=10, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
New P1 trial
|
cyclophosphamide • CB CAR-NK019
3years
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL (clinicaltrials.gov)
P1, N=48, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
Enrollment open
|
CD19 (CD19 Molecule)
|
CD19 expression • CD20 negative
|
CB CAR-NK019
over3years
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL (clinicaltrials.gov)
P1, N=48, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
New P1 trial
|
CD19 (CD19 Molecule)
|
CD19 expression • CD20 negative
|
CB CAR-NK019
Share via
